Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Status:
Completed
Trial end date:
2019-01-09
Target enrollment:
Participant gender:
Summary
This study is designed to determine the maximal tolerated dose of Ruxolitinib in combination
with nilotinib in patients with chronic myeloid leukemia (CML).
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute